What is the evidence difference between DSIP and Selank?

DSIP was tested in small intravenous insomnia studies with conflicting findings. A Selank study compared it with medazepam in 62 people with generalized anxiety disorder or neurasthenia. Different populations and outcomes prevent a direct efficacy ranking.

Does DSIP have human sleep evidence?

Yes, but the small studies conflict. The 2026 FDA assessment found the intravenous evidence inconclusive and no effectiveness study for the proposed subcutaneous route.

Is the DSIP and Selank combination established?

The studies cited here did not test the combination, so they cannot establish its safety or benefit.

DSIP vs Selank: Sleep and Anxiety Study Evidence

Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.

What each study question was

DSIP (emideltide) was studied mainly for sleep. Small intravenous studies in people with insomnia reported some improvements (PMID 7028502; PMID 3622582). Later placebo-controlled studies found effects that were weak or of little clinical significance (PMID 3583493; PMID 1299794). FDA’s 2026 review called the human intravenous evidence inconclusive and found no effectiveness study for the proposed subcutaneous route (FDA emideltide briefing, pp. 24–31). The evidence for a human insomnia benefit is very low.

Selank was studied for anxiety-related symptoms in a Russian-language report. In one randomized comparative study, 30 participants received Selank and 32 received medazepam; the 62 participants had generalized anxiety disorder or neurasthenia. The authors reported similar anxiolytic effects on their measures, but this active-comparator study was small and did not answer whether Selank treats insomnia (PMID 18454096). Its results cannot be translated into a head-to-head ranking against DSIP.

Reader question	DSIP evidence	Selank evidence
Sleep in people with insomnia	Small intravenous studies, with conflicting results and uncertain clinical benefit	The Selank anxiety study did not test this outcome
Anxiety-related symptoms	The cited DSIP sleep studies do not establish an anxiety treatment effect	One small randomized comparison with medazepam in a mixed anxiety/neurasthenia group
Using both together	No combination result in these cited studies	No combination result in these cited studies

What the evidence cannot settle

The compounds were studied in different populations for different outcomes. A publication count, mechanism hypothesis, or response in a different condition cannot rank their clinical effectiveness. The reviewed studies also provide no basis for calling a DSIP–Selank combination compatible or safe. FDA’s 2026 emideltide briefing is a regulatory proposal and evidence assessment, not a final approval decision; it proposed against adding emideltide free base and acetate to the 503A bulks list (FDA briefing, pp. 52–55). This comparison makes no current-country approval claim for Selank because no primary regulatory record was verified for that claim.

This page is for research education. It is not treatment, dosing, combination, or purchasing guidance.

DSIP vs Selank: What Was Studied?

DSIP

Selank

What each study question was

What the evidence cannot settle

View Full Dossiers

Stay Updated on Peptide Comparisons